NeuLumEx Side Effects Center

Last updated on RxList: 8/25/2022
NeuLumEx Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

What Is NeuLumEX?

NeuLumEX (barium sulfate suspension 0.1%) is a positive contrast agent for radiographic studies for use in computed tomography (CT) to opacify the gastrointestinal (GI) tract.

What Are Side Effects of NeuLumEX?

Side effects of NeuLumEX include:

  • nausea, 
  • vomiting
  • diarrhea,
  • abdominal cramping, and
  • allergic reactions. 

NeuLumEx may cause serious side effects including:

  • hives, 
  • difficulty breathing, 
  • swelling of your face, lips, tongue, or throat, 
  • bloating, 
  • severe constipation, 
  • severe cramping, 
  • nausea, 
  • vomiting, 
  • abdominal pain, 
  • chest pain or pressure, 
  • anxiety, 
  • blood in your urine, 
  • blurred vision, 
  • easy bruising, 
  • confusion
  • cough, 
  • vomit that looks like coffee grounds, 
  • black or tarry stools,
  • fainting
  • lightheadedness
  • slow or fast heartbeat, 
  • itching, 
  • skin rash
  • wheezing
  • bleeding that will not stop, 
  • redness of the skin
  • sweating, 
  • tiredness, and 
  • weakness

Get medical help right away, if you have any of the symptoms listed above.

Seek medical care or call 911 at once if you have the following serious side effects:

  • Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
  • Serious heart symptoms such as fast, irregular, or pounding heartbeats; fluttering in your chest; shortness of breath; and sudden dizziness, lightheartedness, or passing out;
  • Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors.

This document does not contain all possible side effects and others may occur. Check with your physician for additional information about side effects.

Dosage for NeuLumEX

The volume of NeuLumEX suspension to be administered will depend on the degree and extent of contrast required in the area(s) under examination and on the technique employed.

The patient should begin drinking NeuLumEX approximately 20 – 30 minutes prior to the scheduled procedure. It is recommended that the patient consume multiple bottles, about 900 mL to 1,350 mL total volume prior to the exam or use as directed by physician. 

NeuLumEX In Children

No data is available regarding NeuLumEX use for patients under 18 years. 

What Drugs, Substances, or Supplements Interact with NeuLumEX?

NeuLumEX may interact with other medicines taken at the same time.

Tell your doctor all medications and supplements you use.

NeuLumEX During Pregnancy and Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant before using NeuLumEX. Radiation is known to cause harm to the unborn fetus exposed in utero. Therefore, radiographic procedures should only be used when, in the judgment of the physician, its use is deemed essential to the welfare of the pregnant patient. Barium sulfate products may be used during lactation. Consult your doctor before breastfeeding. 

Additional Information

Our NeuLumEX (barium sulfate suspension 0.1%) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

QUESTION

About how much does an adult human brain weigh? See Answer
NeuLumEx Professional Information

SIDE EFFECTS

Adverse reactions, such as nausea, vomiting, diarrhea and abdominal cramping, accompanying the use of barium sulfate formulations are infrequent and usually mild. Severe reactions (approximately 1 in 1,000,000) and fatalities (approximately 1 in 10,000,000) have occurred. Procedural complications are rare, but may include aspiration pneumonitis, granuloma formation, intravasation, embolization and peritonitis following intestinal perforation, vasovagal and syncopal episodes, and fatalities.

Allergic Reactions

Due to the increased likelihood of allergic reactions in atopic patients, it is important that a complete history of known and suspected allergies as well as allergic-like symptoms, e.g., rhinitis, bronchial asthma, eczema and urticaria, be obtained prior to any medical procedure utilizing these products. A mild allergic reaction would most likely include generalized pruritus, erythema or urticaria (approximately 1 in 250,000). Such reactions will generally respond to an antihistamine such as 50 mg of diphenhydramine or its equivalent. In the rarer, more serious reactions (approximately 1 in 1,000,000) laryngeal edema, bronchospasm or hypotension could develop. Severe reactions which may require emergency measures are often characterized by peripheral vasodilation, hypotension, reflex tachycardia, dyspnea, agitation, confusion and cyanosis, progressing to unconsciousness. Treatment should be initiated immediately with 0.3 to 0.5 cc of 1:1000 epinephrine subcutaneously. If bronchospasm predominates, 0.25 to 0.50 grams of intravenous aminophylline should be given slowly. Appropriate vasopressors might be required. Adrenocorticosteroids, even if given intravenously, exert no significant effect on the acute allergic reactions for a few hours. The administration of these agents should not be regarded as emergency measures for the treatment of allergic reactions. Apprehensive patients may develop weakness, pallor, tinnitus, diaphoresis and bradycardia following the administration of any diagnostic agent. Such reactions are usually non-allergic in nature and are best treated by having the patient lie flat for an additional 10 to 30 minutes under observation.

DRUG INTERACTIONS

The presence of barium sulfate formulations in the GI tract may alter the absorption of therapeutic agents taken concomitantly. In order to minimize any potential change in absorption, the separate administration of barium sulfate from that of other agents should be considered.

Read the entire FDA prescribing information for NeuLumEx (Barium Sulfate)

SLIDESHOW

Digestive Disorders: Common Misconceptions See Slideshow

© NeuLumEx Patient Information is supplied by Cerner Multum, Inc. and NeuLumEx Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors